• vcard
  • Education
    • J.D., Boston University School of Law, 1995, Concentration in Intellectual Property, with honors
    • B.S., Bates College, 1990, Biology
  • Bar Jurisdictions
    • Massachusetts, 1995
    • District of Columbia, 1996
    • Admitted to practice before the United States Patent and Trademark Office, 1992

Michael Siekman focuses his practice on a range of intellectual property matters, including patent prosecution, licensing and post-grant proceedings and litigation. Leveraging over 25 years of experience, Michael has built in-depth patent portfolios, advising clients in the biotechnology and pharmaceutical industries.

Michael keeps clients’ business goals in mind as he regularly provides legal counsel in the litigation matters, including Hatch-Waxman matters, and post-grant solutions for biosimilars. He has successfully led matters before the Patent Trial and Appeal Board (PTAB) and the European Patent Office. His licensing practice involves IP-related aspects of mergers, acquisitions, IPOs and other financing and licensing programs.

  • Lead counsel in two IPRs defending a patent covering an antibody product with annual sales of $100 million for longtime client BTG International Inc. Obtained termination of IPR with parallel ITC proceeding and denial of institution of second IPR.
  • Lead counsel in four IPRs defending four Cold Spring Harbor Laboratory patents relating to short hairpin RNA (shRNA). Obtained denial of institution of all four IPRs, preserving Cold Spring Harbor’s robust and widely licensed shRNA patent portfolio.
  • Lead counsel in interference for Dyax against key competitor. Invalidated competitor’s patent and obtained patent to same invention by proving 11 months of diligence.
  • Defended IP diligence on biotechnology client in acquisition valued at $6.5 billion.
  • Obtained seminal patents in the fields of gene therapy, phage display, yeast display, and the transgenic production of proteins in animals.
  • Prosecuted one of the most widely licensed biotechnology patent portfolios, with projected milestones and royalties of several hundred million dollars per year.
  • Directed the patent prosecution for a life­saving biologic,including a successful appeal to the Court of Appeals for the Federal Circuit.
  • Obtained Patent Term Extensions and coordinated
    Supplementary Protection Certificate strategies for several

text icon Publications & Presentations
Quoted, Law 360
April 26, 2019
text icon Publications & Presentations
Biopharma IPR Trends
Co-author, Life Science Leader
May 11, 2017
text icon Publications & Presentations
Impact of Post-Grant Proceedings on Biologics and Biosimilars
Co-author, Bloomberg BNA
April 15, 2016
text icon Publications & Presentations
PTAB Surprises Some by Using Its Standard Operating Procedures to Assert Control of Its Case Law
Co-author, BNA’s Patent, Trademark & Copyright Journal
April 3, 2015
text icon Publications & Presentations
To Predict How the Board Will Decide Issues in Inter Partes Review Proceedings, Look to Prior Board Decisions in Contested Cases
Author, Bloomberg BNA
February 1, 2014
text icon Publications & Presentations
Recovering Patent Life with Patent Term Extension
Author, BioPharma
December 1, 2013
text icon Publications & Presentations
Post-grant review under American Invest Act
Author, Intellectual Property Magazine
January 1, 2012
text icon Publications & Presentations
Post-Grant Oppositions Under Patent Reform
Author, Intellectual Property Watch-Inside Views
November 14, 2011
text icon Publications & Presentations
Be prepared for biosimilars
Author, Managing Intellectual Property
November 1, 2010
text icon Publications & Presentations
Risks of False Marking: Reducing Your Exposure
Author, Intellectual Property & Technology Law Journal
July 1, 2010